Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide + semaglutide in type 2 diabetes
NCT04982575Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cagrilintide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2021; status: completed.
02
Drugs
cagrilintide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04982575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982575.